skip to main content
Language:
Search Limited to: Search Limited to: Resource type Show Results with: Show Results with: Search type Index

Results 1 - 20 of 473  for All Library Resources

Results 1 2 3 4 5 next page
Show only
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Are PCSK9 Inhibitors the Next Breakthrough in the Cardiovascular Field?
Material Type:
Article
Add to My Research

Are PCSK9 Inhibitors the Next Breakthrough in the Cardiovascular Field?

Journal of the American College of Cardiology, 2015-06, Vol.65 (24), p.2638-2651 [Peer Reviewed Journal]

American College of Cardiology Foundation ;2015 American College of Cardiology Foundation ;Copyright © 2015 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved. ;Copyright Elsevier Limited Jun 23, 2015 ;ISSN: 0735-1097 ;EISSN: 1558-3597 ;DOI: 10.1016/j.jacc.2015.05.001 ;PMID: 26088304

Full text available

2
The P-Glycoprotein Transport System and Cardiovascular Drugs
Material Type:
Article
Add to My Research

The P-Glycoprotein Transport System and Cardiovascular Drugs

Journal of the American College of Cardiology, 2013-06, Vol.61 (25), p.2495-2502 [Peer Reviewed Journal]

American College of Cardiology Foundation ;2013 American College of Cardiology Foundation ;2014 INIST-CNRS ;Copyright © 2013 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved. ;Copyright Elsevier Limited Jun 25, 2013 ;ISSN: 0735-1097 ;EISSN: 1558-3597 ;DOI: 10.1016/j.jacc.2013.02.058 ;PMID: 23563132 ;CODEN: JACCDI

Full text available

3
Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events
Material Type:
Article
Add to My Research

Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events

The New England journal of medicine, 2015-04, Vol.372 (16), p.1500-1509 [Peer Reviewed Journal]

Copyright © 2015 Massachusetts Medical Society. All rights reserved. ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1500858 ;PMID: 25773607

Full text available

4
Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials
Material Type:
Article
Add to My Research

Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials

The Lancet (British edition), 2014-03, Vol.383 (9921), p.955-962 [Peer Reviewed Journal]

Elsevier Ltd ;2014 Elsevier Ltd ;2015 INIST-CNRS ;Copyright © 2014 Elsevier Ltd. All rights reserved. ;Copyright Elsevier Limited Mar 15, 2014 ;Distributed under a Creative Commons Attribution 4.0 International License ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(13)62343-0 ;PMID: 24315724 ;CODEN: LANCAO

Full text available

5
Cognitive Function in a Randomized Trial of Evolocumab
Material Type:
Article
Add to My Research

Cognitive Function in a Randomized Trial of Evolocumab

The New England journal of medicine, 2017-08, Vol.377 (7), p.633-643 [Peer Reviewed Journal]

Copyright © 2017 Massachusetts Medical Society. All rights reserved. ;info:eu-repo/semantics/openAccess ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1701131 ;PMID: 28813214

Full text available

6
Inflammatory and Cholesterol Risk in the FOURIER Trial
Material Type:
Article
Add to My Research

Inflammatory and Cholesterol Risk in the FOURIER Trial

Circulation (New York, N.Y.), 2018-07, Vol.138 (2), p.131-140 [Peer Reviewed Journal]

2018 by the American College of Cardiology Foundation and the American Heart Association, Inc. ;2018 American Heart Association, Inc. ;ISSN: 0009-7322 ;EISSN: 1524-4539 ;DOI: 10.1161/CIRCULATIONAHA.118.034032 ;PMID: 29530884

Full text available

7
Atherothrombotic Risk Stratification and Ezetimibe for Secondary Prevention
Material Type:
Article
Add to My Research

Atherothrombotic Risk Stratification and Ezetimibe for Secondary Prevention

Journal of the American College of Cardiology, 2017-02, Vol.69 (8), p.911-921 [Peer Reviewed Journal]

American College of Cardiology Foundation ;2017 American College of Cardiology Foundation ;Copyright © 2017 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved. ;Copyright Elsevier Limited Feb 28, 2017 ;ISSN: 0735-1097 ;EISSN: 1558-3597 ;DOI: 10.1016/j.jacc.2016.11.070 ;PMID: 28231942

Full text available

8
Non–Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation and Valvular Heart Disease
Material Type:
Article
Add to My Research

Non–Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation and Valvular Heart Disease

Journal of the American College of Cardiology, 2017-03, Vol.69 (11), p.1363-1371 [Peer Reviewed Journal]

The Authors ;2017 The Authors ;Copyright © 2017 The Authors. Published by Elsevier Inc. All rights reserved. ;Copyright Elsevier Limited Mar 21, 2017 ;ISSN: 0735-1097 ;EISSN: 1558-3597 ;DOI: 10.1016/j.jacc.2016.12.038 ;PMID: 28302287

Full text available

9
Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial
Material Type:
Article
Add to My Research

Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial

The Lancet (British edition), 2015-06, Vol.385 (9984), p.2288-2295 [Peer Reviewed Journal]

Elsevier Ltd ;2015 Elsevier Ltd ;Copyright © 2015 Elsevier Ltd. All rights reserved. ;Copyright Elsevier Limited Jun 6, 2015 ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(14)61943-7 ;PMID: 25769361 ;CODEN: LANCAO

Full text available

10
Efficacy and Safety of Evolocumab in Chronic Kidney Disease in the FOURIER Trial
Material Type:
Article
Add to My Research

Efficacy and Safety of Evolocumab in Chronic Kidney Disease in the FOURIER Trial

Journal of the American College of Cardiology, 2019-06, Vol.73 (23), p.2961-2970 [Peer Reviewed Journal]

Copyright © 2019 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved. ;2019. American College of Cardiology Foundation ;ISSN: 0735-1097 ;ISSN: 1558-3597 ;EISSN: 1558-3597 ;DOI: 10.1016/j.jacc.2019.03.513 ;PMID: 31196453

Full text available

11
Valvular Heart Disease Patients on Edoxaban or Warfarin in the ENGAGE AF-TIMI 48 Trial
Material Type:
Article
Add to My Research

Valvular Heart Disease Patients on Edoxaban or Warfarin in the ENGAGE AF-TIMI 48 Trial

Journal of the American College of Cardiology, 2017-03, Vol.69 (11), p.1372-1382 [Peer Reviewed Journal]

The Authors ;2017 The Authors ;Copyright © 2017 The Authors. Published by Elsevier Inc. All rights reserved. ;Copyright Elsevier Limited Mar 21, 2017 ;ISSN: 0735-1097 ;EISSN: 1558-3597 ;DOI: 10.1016/j.jacc.2016.12.031 ;PMID: 28302288

Full text available

12
Nonvitamin K Anticoagulant Agents in Patients With Advanced Chronic Kidney Disease or on Dialysis With AF
Material Type:
Article
Add to My Research

Nonvitamin K Anticoagulant Agents in Patients With Advanced Chronic Kidney Disease or on Dialysis With AF

Journal of the American College of Cardiology, 2016-06, Vol.67 (24), p.2888-2899 [Peer Reviewed Journal]

American College of Cardiology Foundation ;2016 American College of Cardiology Foundation ;Copyright © 2016 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved. ;Copyright Elsevier Limited Jun 21, 2016 ;ISSN: 0735-1097 ;EISSN: 1558-3597 ;DOI: 10.1016/j.jacc.2016.02.082 ;PMID: 27311528

Full text available

13
PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor's role[S]
Material Type:
Article
Add to My Research

PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor's role[S]

Journal of lipid research, 2016-06, Vol.57 (6), p.1086-1096 [Peer Reviewed Journal]

2016 © 2016 ASBMB. Currently published by Elsevier Inc; originally published by American Society for Biochemistry and Molecular Biology. ;Copyright © 2016 by the American Society for Biochemistry and Molecular Biology, Inc. ;Copyright © 2016 by the American Society for Biochemistry and Molecular Biology, Inc. 2016 ;ISSN: 0022-2275 ;EISSN: 1539-7262 ;DOI: 10.1194/jlr.P065334 ;PMID: 27102113

Full text available

14
Rationale and design of the Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trial
Material Type:
Article
Add to My Research

Rationale and design of the Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trial

The American heart journal, 2016-03, Vol.173, p.94-101 [Peer Reviewed Journal]

Mosby, Inc. ;2015 Elsevier Inc. ;Copyright © 2015 Elsevier Inc. All rights reserved. ;Copyright Elsevier Limited Mar 1, 2016 ;ISSN: 0002-8703 ;EISSN: 1097-6744 ;DOI: 10.1016/j.ahj.2015.11.015 ;PMID: 26920601

Full text available

15
Efficacy and Safety of Edoxaban in Elderly Patients With Atrial Fibrillation in the ENGAGE AF–TIMI 48 Trial
Material Type:
Article
Add to My Research

Efficacy and Safety of Edoxaban in Elderly Patients With Atrial Fibrillation in the ENGAGE AF–TIMI 48 Trial

Journal of the American Heart Association, 2016-05, Vol.5 (5), p.n/a [Peer Reviewed Journal]

2016 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell. ;ISSN: 2047-9980 ;EISSN: 2047-9980 ;DOI: 10.1161/JAHA.116.003432 ;PMID: 27207971

Full text available

16
Reduction in Lipoprotein(a) With PCSK9 Monoclonal Antibody Evolocumab (AMG 145)
Material Type:
Article
Add to My Research

Reduction in Lipoprotein(a) With PCSK9 Monoclonal Antibody Evolocumab (AMG 145)

Journal of the American College of Cardiology, 2014-04, Vol.63 (13), p.1278-1288 [Peer Reviewed Journal]

American College of Cardiology Foundation ;2014 American College of Cardiology Foundation ;Copyright Elsevier Limited Apr 8, 2014 ;ISSN: 0735-1097 ;EISSN: 1558-3597 ;DOI: 10.1016/j.jacc.2014.01.006

Full text available

17
Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study
Material Type:
Article
Add to My Research

Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study

The Lancet (British edition), 2012-12, Vol.380 (9858), p.2007-2017 [Peer Reviewed Journal]

Elsevier Ltd ;2012 Elsevier Ltd ;2014 INIST-CNRS ;Copyright © 2012 Elsevier Ltd. All rights reserved. ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(12)61770-X ;PMID: 23141813 ;CODEN: LANCAO

Full text available

18
Left atrial structure and function in atrial fibrillation: ENGAGE AF-TIMI 48
Material Type:
Article
Add to My Research

Left atrial structure and function in atrial fibrillation: ENGAGE AF-TIMI 48

European heart journal, 2014-06, Vol.35 (22), p.1457-1465 [Peer Reviewed Journal]

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2013. For permissions please email: journals.permissions@oup.com. ;Distributed under a Creative Commons Attribution 4.0 International License ;Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2013. For permissions please email: journals.permissions@oup.com. 2013 ;ISSN: 0195-668X ;EISSN: 1522-9645 ;DOI: 10.1093/eurheartj/eht500 ;PMID: 24302269

Full text available

19
The Effect of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition on the Risk of Venous Thromboembolism
Material Type:
Article
Add to My Research

The Effect of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition on the Risk of Venous Thromboembolism

Circulation (New York, N.Y.), 2020-05, Vol.141 (20), p.1600-1607 [Peer Reviewed Journal]

2020 by the American College of Cardiology Foundation and the American Heart Association, Inc. ;ISSN: 0009-7322 ;EISSN: 1524-4539 ;DOI: 10.1161/CIRCULATIONAHA.120.046397 ;PMID: 32223429

Full text available

20
Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: Design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation–Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF–TIMI 48)
Material Type:
Article
Add to My Research

Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: Design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation–Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF–TIMI 48)

The American heart journal, 2010-10, Vol.160 (4), p.635-641.e2 [Peer Reviewed Journal]

Mosby, Inc. ;2010 Mosby, Inc. ;2015 INIST-CNRS ;Copyright © 2010 Mosby, Inc. All rights reserved. ;Copyright Elsevier Limited Oct 2010 ;ISSN: 0002-8703 ;EISSN: 1097-6744 ;DOI: 10.1016/j.ahj.2010.06.042 ;PMID: 20934556 ;CODEN: AHJOA2

Full text available

Results 1 - 20 of 473  for All Library Resources

Results 1 2 3 4 5 next page

Personalize your results

  1. Edit

Refine Search Results

Expand My Results

  1.   

Show only

  1. Peer-reviewed Journals (443)

Refine My Results

New Records 

  1. New From Last Month  (1)
  2. New From Last 3 Month  (9)
  3. More options open sub menu

Language 

  1. English  (472)
  2. Japanese  (35)
  3. Portuguese  (2)
  4. Russian  (2)
  5. Norwegian  (1)
  6. More options open sub menu

Searching Remote Databases, Please Wait